Clinical Studies

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells. Targeting caPCNA with drugs holds promise as a novel therapeutic option with potential for widespread use across multiple cancer types and the possibility of a low risk for side effects. The compound being studied here is a caPCNA inhibitor and has been tested at various doses in healthy dogs with the only side effect noted being diarrhea at higher doses. We now propose a study to investigate the tolerability of this compound in dogs with cancer with the goal of then advancing this drug into future clinical trials that evaluate its use for specific cancer types. The study duration is 35 days and consists of a total of 7 hospital visits. The trial is fully funded with no costs to the owner.

ELIGIBILITY CRITERIA

• Any dog with a measurable cancer that has been diagnosed via biopsy or fine needle aspiration
• No previous chemotherapy within 10 days of study entry

PARTICIPATING HOSPITALS

• Massachusetts Veterinary Referral Hospital, Woburn, MA
• Peak Veterinary Referral Center, Williston, VT
• WVRC – Waukesha, Waukesha, WI